AZoRobotics recently featured the new Lumea and Tempus digital pathology and artificial intelligence collaboration. More advancements are happening between pathology and artificial intelligence every year. This one is particularly exciting because…
Lumea, a leader in digital pathology solutions, has chosen Tempus, a leader in artificial intelligence and precision medicine, to create AI-enabled solutions LEHI, UTAH, UNITED STATES, August 4, 2022 — Lumea…
An ancillary or molecular test is a medical test for a patient that is not a part of the original study design. There are a wide variety of ancillary tests…
LEHI, UTAH, USA — June 1, 2022 — Lumea Inc, a global leader in integrated digital pathology solutions, is pleased to announce the first-of-its-kind Digital Diagnostic Summit in Park City,…
Lumea Inc, a global leader in integrated digital pathology solutions, is pleased to announce the first-of-its-kind Digital Diagnostic Summit in Park City, Utah. Today, Lumea announces the presenters for the…
*BxLink has not been approved by the FDA for digital primary diagnosis. Refer to CAP guidelines regarding the use of digital pathology technologies.
Recent Comments